Management of Hypertension in Patients with Cardiac Disease: Use of Renin-Angiotensin Blocking Agents

American Journal of Medicine

Volumn 121, Issue 8 SUPPL. 1, 2008, Pages

  Prisant, L Michael ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Heart failure; High cardiovascular risk; Hypertension; Left ventricular dysfunction

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; THROMBOCYTE SLOWING FACTOR; TRANDOLAPRIL; VERAPAMIL;

ADD ON THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC HEART FAILURE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HORMONE INHIBITION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; HEART DISEASES; HUMANS; HYPERTENSION; MORBIDITY; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 47049114771     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.05.017     Document Type: Article

References (34)

1. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
2. Pfeffer M.A., Braunwald E., Moye L.A., et al., SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 327 (1992) 669-677
3. Køber L., Torp-Pedersen C., Carlsen J.E., et al., Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333 (1995) 1670-1676
4. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al., Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. [published correction appears in N Engl J Med. 2004;350:203]. N Engl J Med 349 (2003) 1893-1906
5. Pfeffer M.A., Swedberg K., Granger C.B., et al., CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
6. Gohlke P., Lamberty V., Kuwer I., Bartenbach S., Schnell A., and Unger T. Vascular remodeling in systemic hypertension. Am J Cardiol 71 (1993) 2E-7E
7. Jalil J.E., Janicki J.S., Pick R., and Weber K.T. Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension: response to captopril. Am J Hypertens 4 pt 1 (1991) 51-55
8. McVeigh G.E. Effects of perindopril on cardiovascular remodeling. Am J Cardiol 88 suppl 7A (2001) 28i-35i
9. Tamura T., Said S., Harris J., et al. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation 102 (2000) 253-259
10. Yusuf S., Pepine C.J., Garces C., et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340 (1992) 1173-1178
11. Rutherford J.D., Pfeffer M.A., Moye L.A., et al. Effects of captopril on ischemic events after myocardial infarction: results of the Survival and Ventricular Enlargement trial. Circulation 90 (1994) 1731-1738
12. Yusuf S., Sleight P., Pogue J., et al., Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
13. Svensson P., de Faire U., Sleight P., Yusuf S., and Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 38 (2001) E28-E32
14. Fox K.M., and EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
15. Braunwald E., Domanski M.J., Fowler S.E., et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
17. Appel L.J. The verdict from ALLHAT-thiazide diuretics are the preferred initial therapy for hypertension. JAMA 288 (2002) 3039-3042
18. Messerli F.H. ALLHAT, or the soft science of the secondary end point. Ann Intern Med 139 (2003) 777-780
19. Davis B.R., Furberg C.D., Wright Jr. J.T., et al. ALLHAT: setting the record straight. Ann Intern Med 141 (2004) 39-46
20. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al., INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST), a randomized controlled trial. JAMA 290 (2003) 2805-2816
21. Vasan R.S., Benjamin E.J., and Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 26 (1995) 1565-1574
22. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003) 777-781
23. Cleland J.G., Tendera M., Adamus J., et al. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 27 (2006) 2338-2345
24. Carson P., Massie B.M., McKelvie R., et al. The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial: rationale and design. J Card Fail 11 (2005) 576-585
25. Koren M.J., Devereux R.B., Casale P.N., et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114 (1991) 345-352
26. Mensah G.A., Pappas T.W., Koren M.J., et al. Comparison of classification of the severity of hypertension by blood pressure level and by World Health Organization criteria in the prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. J Hypertens 11 (1993) 1429-1440
27. Mathew J., Sleight P., Lonn E., et al., Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104 (2001) 1615-1621
28. Ruzicka M., Yuan B., Harmsen E., and Leenen F.H. The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats: effects of angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker. Circulation 87 (1993) 921-930
29. Onodera T., Okazaki F., Miyazaki H., et al. Perindopril reverses myocyte remodeling in the hypertensive heart. Hypertens Res 25 (2002) 85-90
30. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
31. Devereux R.B., Dahlof B., Gerdts E., et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110 (2004) 1456-1462
32. Kenchaiah S., Davis B.R., Braunwald E., et al. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: insights from the Survival and Ventricular Enlargement trial. Am Heart J 148 (2004) 356-364
33. Kenchaiah S., Pfeffer M.A., St. John Sutton M., et al. Effect of antecedent systemic hypertension on subsequent left ventricular dilation after acute myocardial infarction (from the Survival and Ventricular Enlargement trial). Am J Cardiol 94 (2004) 1-8
34. Lewis E.F., Moye L.A., Rouleau J.L., et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol 42 (2003) 1446-1453